These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 25485735)

  • 61. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
    Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
    Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.
    Berenguer J; Alvarez-Pellicer J; Martín PM; López-Aldeguer J; Von-Wichmann MA; Quereda C; Mallolas J; Sanz J; Tural C; Bellón JM; González-García J;
    Hepatology; 2009 Aug; 50(2):407-13. PubMed ID: 19575364
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Mortality is not increased in SARS-CoV-2 infected persons with hepatitis C virus infection.
    Butt AA; Yan P; Chotani RA; Shaikh OS
    Liver Int; 2021 Aug; 41(8):1824-1831. PubMed ID: 33534931
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Disease outcomes in a cohort of women in Ireland infected by hepatitis C-contaminated anti-D immunoglobulin during 1970s.
    Garvey P; Murphy N; Flanagan P; Brennan A; Courtney G; Crosbie O; Crowe J; Hegarty J; Lee J; McIver M; McNulty C; Murray F; Nolan N; O'Farrelly C; Stewart S; Tait M; Norris S; Thornton L
    J Hepatol; 2017 Dec; 67(6):1140-1147. PubMed ID: 28843656
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort).
    Trinchet JC; Bourcier V; Chaffaut C; Ait Ahmed M; Allam S; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Goria O; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Buffet C; Bacq Y; Wartelle C; Dao T; Benhamou Y; Pilette C; Silvain C; Christidis C; Capron D; Thiefin G; Hillaire S; Di Martino V; Nahon P; Chevret S;
    Hepatology; 2015 Sep; 62(3):737-50. PubMed ID: 25678021
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Rates and characteristics of SARS-CoV-2 infection in persons with hepatitis C virus infection.
    Butt AA; Yan P
    Liver Int; 2021 Jan; 41(1):76-80. PubMed ID: 33006798
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Natural history of hepatitis C.
    Alberti A; Chemello L; Benvegnù L
    J Hepatol; 1999; 31 Suppl 1():17-24. PubMed ID: 10622555
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Long-term outcome of hepatitis B and hepatitis C virus co-infection and single HBV infection acquired in youth.
    Zampino R; Marrone A; Merola A; Trani B; Cirillo G; Karayiannis P; Coppola N; Zappalà R; Utili R; Ruggiero G; Adinolfi LE
    J Med Virol; 2009 Dec; 81(12):2012-20. PubMed ID: 19856471
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Impact of common risk factors of fibrosis progression in chronic hepatitis C.
    Rüeger S; Bochud PY; Dufour JF; Müllhaupt B; Semela D; Heim MH; Moradpour D; Cerny A; Malinverni R; Booth DR; Suppiah V; George J; Argiro L; Halfon P; Bourlière M; Talal AH; Jacobson IM; Patin E; Nalpas B; Poynard T; Pol S; Abel L; Kutalik Z; Negro F
    Gut; 2015 Oct; 64(10):1605-15. PubMed ID: 25214320
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C-Related Compensated Cirrhosis.
    Mohanty A; Tate JP; Garcia-Tsao G
    Gastroenterology; 2016 Feb; 150(2):430-40.e1. PubMed ID: 26484707
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of host-related factors on the intensity of liver fibrosis in patients with chronic hepatitis C virus infection.
    Costa LB; Ferraz ML; Perez RM; Ferreira AS; Matos CA; Lanzoni VP; Silva AE
    Braz J Infect Dis; 2002 Oct; 6(5):219-24. PubMed ID: 12495603
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Data mining of routine laboratory tests can predict liver disease progression in Egyptian diabetic patients with hepatitis C virus (G4) infection: a cohort study of 71 806 patients.
    Saad Y; Awad A; Alakel W; Doss W; Awad T; Mabrouk M
    Eur J Gastroenterol Hepatol; 2018 Feb; 30(2):201-206. PubMed ID: 29099423
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Increasing prevalence of cirrhosis among U.S. adults aware or unaware of their chronic hepatitis C virus infection.
    Udompap P; Mannalithara A; Heo NY; Kim D; Kim WR
    J Hepatol; 2016 May; 64(5):1027-1032. PubMed ID: 26809112
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Progression of the FIB-4 index among patients with chronic HCV infection and early liver disease.
    Krassenburg LAP; Maan R; Puenpatom A; Erler NS; Welsch C; van Hees S; Cerrhoci O; Vermehren J; de Knegt RJ; Hansen BE; Zeuzem S; Vanwolleghem T; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
    BMJ Open Gastroenterol; 2023 Dec; 10(1):. PubMed ID: 38637963
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The epidemiology of hepatitis C infection in the United States.
    Rustgi VK
    J Gastroenterol; 2007 Jul; 42(7):513-21. PubMed ID: 17653645
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus.
    Puoti M; Lorenzini P; Cozzi-Lepri A; Gori A; Mastroianni C; Rizzardini G; Mazzarello G; Antinori A; d'Arminio Monforte A; Girardi E;
    Clin Microbiol Infect; 2017 Apr; 23(4):267.e1-267.e4. PubMed ID: 27956268
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparing Child-Pugh, MELD, and FIB-4 to Predict Clinical Outcomes in Hepatitis C Virus-Infected Persons: Results From ERCHIVES.
    Butt AA; Ren Y; Lo Re V; Taddei TH; Kaplan DE
    Clin Infect Dis; 2017 Jul; 65(1):64-72. PubMed ID: 28369305
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prognosis of 1169 hepatitis C chronically infected patients with decompensated cirrhosis in the predirect-acting antiviral era.
    McDonald SA; Innes HA; Aspinall E; Hayes PC; Alavi M; Valerio H; Goldberg DJ; Hutchinson SJ
    J Viral Hepat; 2017 Apr; 24(4):295-303. PubMed ID: 27885753
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prevalence of cirrhosis in hepatitis C patients in the Chronic Hepatitis Cohort Study (CHeCS): a retrospective and prospective observational study.
    Gordon SC; Lamerato LE; Rupp LB; Holmberg SD; Moorman AC; Spradling PR; Teshale E; Xu F; Boscarino JA; Vijayadeva V; Schmidt MA; Oja-Tebbe N; Lu M
    Am J Gastroenterol; 2015 Aug; 110(8):1169-77; quiz 1178. PubMed ID: 26215529
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters.
    van der Meer AJ; Hansen BE; Fattovich G; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Manns MP; Ieluzzi D; Zeuzem S; Hofmann WP; de Knegt RJ; Veldt BJ; Janssen HL
    Gut; 2015 Feb; 64(2):322-31. PubMed ID: 24815676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.